论文部分内容阅读
目的系统评价拉米夫定与乙肝免疫球蛋白联合应用阻断肝移植后HBV再感染的疗效。方法应用Meta分析的方法比较治疗组(联合应用LAM和HBIG)与对照组(单一应用LAM或HBIG)对移植后HBV再感染率的差异,以比值比(OR)为效应量进行合并分析。结果共纳入研究文献7篇,研究样本360例。OR及95%可信限(95%CI)为0.34(95%CI:0.18,0.64),2组间HBV复发率的差异具有统计学意义(Z=3.33,P=0.001)。各研究之间具有同质性(P=0.310)。结论拉米夫定与乙肝免疫球蛋白联合应用可有效阻断肝移植后HBV再感染,且联合用药的效果优于单一用药。
Objective To systematically evaluate the curative effect of lamivudine combined with hepatitis B immunoglobulin in blocking HBV reinfection after liver transplantation. Methods Meta-analysis was used to compare the rate of re-infection of HBV after treatment with LAM and HBIG in the treatment group (single application of LAM or HBIG) and the odds ratio (OR) Results A total of 7 research papers were included and 360 samples were studied. OR and 95% confidence interval (95% CI) was 0.34 (95% CI: 0.18, 0.64). There was a statistically significant difference in the relapse rate of HBV between the two groups (Z = 3.33, P = 0.001). There was homogeneity among the studies (P = 0.310). Conclusion The combination of lamivudine and hepatitis B immunoglobulin can effectively block HBV re-infection after liver transplantation, and the combination therapy is better than single therapy.